

Bangladesh Support for Measles-Rubella Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Bangladesh			
2. Grant number: 17-BGD-09a-X			
3. Date of Decision Letter: 22 December 2016			
4. Date of the Partnership Framework Agreement: 24 June 2013			
5. Programme title: New vaccine support (NVS), Measles-Rubella MSD			
6. Vaccine type: Measles-Rubella			
7. Requested product presentation and formulation of vaccine: Measles Rubella, 10 dose(s) per vial, LYOPHILISED			
8. Programme duration¹: 2012 - 2017			
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement)			
	2012-2016	2017	Total ²
Programme Budget (US\$)	US\$8,575,522 ³	US\$1,277,500	US\$9,853,022
10. Vaccine introduction grant (in US\$): Not applicable			
11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement) ⁴			
Type of supplies to be purchased with Gavi funds in each year	2012-2016		2017
Number of Measles-Rubella vaccines doses			4,431,400
Annual Amounts (US\$)	US\$8,575,522 ⁵		US\$1,277,500
12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.			
13. Self-procurement: Not applicable			
14. Co-financing obligations: Not applicable			
15. Operational support for campaigns: Not applicable			

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

³ This is the consolidated amount for all previous years.

⁴ This is the amount that Gavi has approved.

⁵ This is the consolidated amount for all previously approved years.

16. Additional reporting requirements: Not applicable													
Reports and other information	Due dates												
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	May												
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat												
<p>17. Financial clarifications: The country is requested to address any recommendations, prioritised needs and strategic actions as described in the High Level Review Panel Report (October 2016)*</p> <p><i>*Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements</i></p>													
<p>18. Other conditions:</p> <p>Country has presented an official request to Gavi to switch from measles vaccine to measles-rubella vaccine for the routine measles second dose with country funding for the equivalent cost of the rubella component. As such, country will make the required payments to UNICEF Supply Division as indicated in the table below.</p> <table border="1"> <thead> <tr> <th></th> <th>2017</th> </tr> </thead> <tbody> <tr> <td>Number of doses of vaccines for Measles Second Dose approved by Gavi.</td> <td>4,431,400</td> </tr> <tr> <td>Amount for vaccines approved by Gavi in US\$ (excluding freight and insurance).</td> <td>1,240,792</td> </tr> <tr> <td>Number of doses of Measles-Rubella vaccine that can be purchased with Gavi support.</td> <td>2,034,085</td> </tr> <tr> <td>Number of doses of Measles-Rubella vaccine to be funded by country.</td> <td>2,397,315</td> </tr> <tr> <td>Amount for Measles-Rubella vaccines to be funded by country in US\$ (excluding freight and insurance).</td> <td>1,462,362</td> </tr> </tbody> </table> <p>In the case of procurement through UNICEF, Gavi-funded vaccines will be purchased only after receipt of full payment of the respective amounts due from Country for the number of doses as indicated in this Decision Letter. Country is required to submit a request for a Cost Estimate to UNICEF, with a clear reference to the approval code and approval year. Country will inform Gavi Secretariat when payment of the respective amount due under this Cost Estimate has been fully made to UNICEF.</p> <p>In the event that country wishes to revert to measles vaccine, country should inform UNICEF and Gavi immediately in order to agree on an appropriate arrangement.</p>			2017	Number of doses of vaccines for Measles Second Dose approved by Gavi.	4,431,400	Amount for vaccines approved by Gavi in US\$ (excluding freight and insurance).	1,240,792	Number of doses of Measles-Rubella vaccine that can be purchased with Gavi support.	2,034,085	Number of doses of Measles-Rubella vaccine to be funded by country.	2,397,315	Amount for Measles-Rubella vaccines to be funded by country in US\$ (excluding freight and insurance).	1,462,362
	2017												
Number of doses of vaccines for Measles Second Dose approved by Gavi.	4,431,400												
Amount for vaccines approved by Gavi in US\$ (excluding freight and insurance).	1,240,792												
Number of doses of Measles-Rubella vaccine that can be purchased with Gavi support.	2,034,085												
Number of doses of Measles-Rubella vaccine to be funded by country.	2,397,315												
Amount for Measles-Rubella vaccines to be funded by country in US\$ (excluding freight and insurance).	1,462,362												

Signed by,



On behalf of Gavi

for: Hind Khatib-Othman
Managing Director, Country Programmes
22 December 2016

Barry Greene
Managing Director
Finance & Operations
The GAVI Alliance